Published in Antimicrob Agents Chemother on March 01, 1992
Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells. Proc Natl Acad Sci U S A (1994) 1.29
Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2',3'-dideoxyinosine in infected resting human lymphocytes. Proc Natl Acad Sci U S A (1994) 0.89
Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob Agents Chemother (1996) 0.88
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (1985) 30.47
T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature (1985) 21.57
Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A (1988) 10.77
Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature (1988) 10.69
Cellular uptake of the tat protein from human immunodeficiency virus. Cell (1988) 10.19
Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science (1990) 10.13
CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science (1986) 9.17
HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature (1987) 7.88
Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science (1989) 7.15
High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci U S A (1990) 6.49
A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature (1988) 6.39
Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci U S A (1989) 6.32
The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science (1987) 6.16
Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase. Science (1991) 5.42
Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. Proc Natl Acad Sci U S A (1986) 5.18
Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc Natl Acad Sci U S A (1987) 5.17
Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature (1989) 4.80
HIV infection is blocked in vitro by recombinant soluble CD4. Nature (1988) 4.58
Rational design of peptide-based HIV proteinase inhibitors. Science (1990) 4.57
Ribozymes as potential anti-HIV-1 therapeutic agents. Science (1990) 4.49
Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science (1987) 4.31
A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research. N Engl J Med (1991) 4.23
A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature (1988) 4.15
Designing CD4 immunoadhesins for AIDS therapy. Nature (1989) 4.00
Soluble CD4 molecules neutralize human immunodeficiency virus type 1. Nature (1988) 3.63
Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science (1988) 3.44
Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet (1988) 3.37
Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci U S A (1990) 3.18
HTLV-III gag protein is processed in yeast cells by the virus pol-protease. Science (1986) 3.06
Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro. Lancet (1985) 3.03
Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science (1990) 2.83
A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. Science (1990) 2.80
Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution. Science (1989) 2.74
Interference with HIV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase. Nature (1987) 2.72
BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob Agents Chemother (1991) 2.66
Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc Natl Acad Sci U S A (1989) 2.62
Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science (1987) 2.51
Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon. Antimicrob Agents Chemother (1987) 2.47
The efficacy of inosine pranobex in preventing the acquired immunodeficiency syndrome in patients with human immunodeficiency virus infection. The Scandinavian Isoprinosine Study Group. N Engl J Med (1990) 2.46
The Ams (altered mRNA stability) protein and ribonuclease E are encoded by the same structural gene of Escherichia coli. Proc Natl Acad Sci U S A (1991) 2.45
The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells. Science (1989) 2.40
Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Ann Intern Med (1990) 2.40
Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions. J Virol (1991) 2.40
An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. Proc Natl Acad Sci U S A (1990) 2.32
A phase I/II study of trichosanthin treatment of HIV disease. AIDS (1990) 2.26
Inhibition of human immunodeficiency virus syncytium formation and virus replication by castanospermine. Proc Natl Acad Sci U S A (1987) 2.25
Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob Agents Chemother (1987) 2.24
Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study. Ann Intern Med (1992) 2.19
Tat and Rev: positive regulators of HIV gene expression. AIDS (1990) 2.18
Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules. Nature (1989) 2.17
Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues. Proc Natl Acad Sci U S A (1989) 2.14
Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues. Nature (1990) 2.13
Biological properties of a CD4 immunoadhesin. Nature (1990) 2.05
Dextran sulphate, a potent anti-HIV agent in vitro having synergism with zidovudine. Lancet (1987) 1.85
The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study. Ann Intern Med (1990) 1.82
Mutations within the RNase H domain of human immunodeficiency virus type 1 reverse transcriptase abolish virus infectivity. J Gen Virol (1991) 1.80
Soluble CD4 enhances simian immunodeficiency virus SIVagm infection. J Virol (1990) 1.79
CD4+ lymphocyte function with early human immunodeficiency virus infection. Proc Natl Acad Sci U S A (1989) 1.78
Aminosugar derivatives as potential anti-human immunodeficiency virus agents. Proc Natl Acad Sci U S A (1988) 1.75
GLQ223: an inhibitor of human immunodeficiency virus replication in acutely and chronically infected cells of lymphocyte and mononuclear phagocyte lineage. Proc Natl Acad Sci U S A (1989) 1.73
A specific inhibitor of cysteine proteases impairs a Vif-dependent modification of human immunodeficiency virus type 1 Env protein. J Virol (1991) 1.72
Combined zidovudine and interferon-alpha therapy in patients with Kaposi sarcoma and the acquired immunodeficiency syndrome (AIDS) Ann Intern Med (1989) 1.71
Effects of passive immunization in patients with the acquired immunodeficiency syndrome-related complex and acquired immunodeficiency syndrome. Proc Natl Acad Sci U S A (1988) 1.69
Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial. Ann Intern Med (1990) 1.65
Alpha-(1-3)- and alpha-(1-6)-D-mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomegalovirus infections in vitro. Antimicrob Agents Chemother (1991) 1.63
Passive immunoneutralization of human immunodeficiency virus in patients with advanced AIDS. Lancet (1988) 1.63
Envelope proteins from clinical isolates of human immunodeficiency virus type 1 that are refractory to neutralization by soluble CD4 possess high affinity for the CD4 receptor. Proc Natl Acad Sci U S A (1991) 1.62
Therapeutic agents with dramatic antiretroviral activity and little toxicity at effective doses: aromatic polycyclic diones hypericin and pseudohypericin. Proc Natl Acad Sci U S A (1988) 1.60
Use of IFN-gamma in patients with AIDS. J Acquir Immune Defic Syndr (1990) 1.59
Receptor-mediated activation of immunodeficiency viruses in viral fusion. Science (1991) 1.56
Effect of recombinant soluble CD4 in rhesus monkeys infected with simian immunodeficiency virus of macaques. Nature (1989) 1.55
Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection. Antimicrob Agents Chemother (1991) 1.48
Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors. Proc Natl Acad Sci U S A (1989) 1.47
Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease. Proc Natl Acad Sci U S A (1990) 1.46
The safety and pharmacokinetics of GLQ223 in subjects with AIDS and AIDS-related complex: a phase I study. AIDS (1990) 1.44
CD4-Pseudomonas exotoxin hybrid protein blocks the spread of human immunodeficiency virus infection in vitro and is active against cells expressing the envelope glycoproteins from diverse primate immunodeficiency retroviruses. Proc Natl Acad Sci U S A (1989) 1.44
Randomised, double-blind, placebo-controlled trial of ditiocarb sodium ('Imuthiol') in human immunodeficiency virus infection. Lancet (1988) 1.43
Suppression of human immunodeficiency virus expression in chronically infected monocytic cells by glutathione, glutathione ester, and N-acetylcysteine. Proc Natl Acad Sci U S A (1991) 1.40
Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. Lancet (1988) 1.36
Oral dextran sulfate (UA001) in the treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Ann Intern Med (1989) 1.28
Incorporation of 12-methoxydodecanoate into the human immunodeficiency virus 1 gag polyprotein precursor inhibits its proteolytic processing and virus production in a chronically infected human lymphoid cell line. Proc Natl Acad Sci U S A (1991) 1.27
Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma. N Engl J Med (1983) 1.26
Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha A. J Infect Dis (1990) 1.25
CD4 immunoadhesin, but not recombinant soluble CD4, blocks syncytium formation by human immunodeficiency virus type 2-infected lymphoid cells. J Virol (1990) 1.20
Polymerase chain reaction evidence for human immunodeficiency virus 1 neutralization by passive immunization in patients with AIDS and AIDS-related complex. Proc Natl Acad Sci U S A (1990) 1.19
Prospects for the control of AIDS by immunizing seropositive individuals. Nature (1987) 1.17
Synergistic activity of granulocyte-macrophage colony-stimulating factor and 3'-azido-3'-deoxythymidine against human immunodeficiency virus in vitro. Antimicrob Agents Chemother (1987) 1.17
CD8+ lymphocytes suppress HIV production by autologous CD4+ cells without eliminating the infected cells from culture. Cell Immunol (1990) 1.17
Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro. Antimicrob Agents Chemother (1989) 1.15
Inhibition of HIV progression by dithiocarb. German DTC Study Group. Lancet (1990) 1.15
Inhibition of human immunodeficiency virus type 1 morphogenesis in T cells by alpha interferon. Antimicrob Agents Chemother (1991) 1.15
NIH conference. Antiretroviral therapy in AIDS. Ann Intern Med (1990) 1.15
Dextran sulfate is poorly absorbed after oral administration. Ann Intern Med (1989) 1.13
Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet. Antimicrob Agents Chemother (1989) 1.13
Production of cytokines by peripheral blood monocytes/macrophages infected with human immunodeficiency virus type 1 (HIV-1). J Infect Dis (1990) 1.11
TAP 29: an anti-human immunodeficiency virus protein from Trichosanthes kirilowii that is nontoxic to intact cells. Proc Natl Acad Sci U S A (1991) 1.09
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA (2000) 7.81
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 6.49
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA (1997) 6.35
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA (1996) 5.29
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA (1998) 4.61
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. JAMA (1998) 4.42
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med (1996) 4.03
Staphylococcus epidermidis infections. Ann Intern Med (1983) 3.57
Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA (2001) 3.28
Zidovudine: five years later. Ann Intern Med (1992) 2.28
Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med (2001) 2.08
Methylation of the viral genome in an in vitro model of herpes simplex virus latency. Proc Natl Acad Sci U S A (1982) 1.56
Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team. J Acquir Immune Defic Syndr (2000) 1.45
Infiltration of the lower respiratory tract by helper/inducer T lymphocytes in HTLV-1-associated adult T-cell leukemia/lymphoma. Am J Med (1991) 1.43
A comparison of two dosing regimens of zidovudine in Thai adults with early symptomatic HIV infection. Conducting clinical HIV trials in South-East Asia. Aust N Z J Med (2000) 1.42
Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS (2000) 1.42
HIV-1 Tat modulates invasion by a bacterial enteric pathogen into a human intestinal cell line. AIDS (1995) 1.39
In vitro modification of human immunodeficiency virus infection by granulocyte-macrophage colony-stimulating factor and gamma interferon. Proc Natl Acad Sci U S A (1986) 1.35
Cytomegalovirus vasculitis. Case reports and review of the literature. Medicine (Baltimore) (1994) 1.24
Host determinants in HIV infection and disease. Part 2: genetic factors and implications for antiretroviral therapeutics. Ann Intern Med (2001) 1.24
Treatment of Listeria monocytogenes infection with trimethoprim-sulfamethoxazole: case report and review of the literature. Rev Infect Dis (1986) 1.22
Didanosine and zidovudine resistance patterns in clinical isolates of human immunodeficiency virus type 1 as determined by a replication endpoint concentration assay. Antimicrob Agents Chemother (1992) 1.22
The herpes simplex virus immediate-early protein, ICP4, is required to potentiate replication of human immunodeficiency virus in CD4+ lymphocytes. J Virol (1989) 1.22
Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis (1998) 1.20
The acute aseptic meningitis syndrome. Infect Dis Clin North Am (1990) 1.20
Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320. Ann Intern Med (2001) 1.18
Temporal cluster of herpes simplex encephalitis: investigation by restriction endonuclease cleavage of viral DNA. J Infect Dis (1980) 1.17
HIV fusion and its inhibition. Antiviral Res (2001) 1.13
Host determinants in HIV infection and disease. Part 1: cellular and humoral immune responses. Ann Intern Med (2001) 1.13
Activation of human immunodeficiency virus by herpes simplex virus. J Infect Dis (1992) 1.13
Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature. Clin Infect Dis (2001) 1.09
Epstein-Barr virus-induced infectious mononucleosis complicated by acute renal failure: case report and review. Clin Infect Dis (1996) 1.05
Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells/mm(3) (ACTG 175). AIDS Clinical Trials Group Protocol 175 Team. J Infect Dis (1998) 1.04
Vitamin D deficiency in HIV-infected postmenopausal Hispanic and African-American women. Osteoporos Int (2010) 1.03
Ganciclovir therapy of severe cytomegalovirus infections in solid-organ transplant recipients. Transplantation (1988) 1.01
Clinical trials using HIV-1 RNA-based primary endpoints: statistical analysis and potential biases. J Acquir Immune Defic Syndr Hum Retrovirol (1999) 0.99
Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team. J Infect Dis (1998) 0.96
Kinetics of sealing for transient electropores in isolated mammalian skeletal muscle cells. Bioelectromagnetics (1999) 0.95
Herpes simplex virus infection of human T-cell subpopulations. Infect Immun (1982) 0.95
Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group. Antimicrob Agents Chemother (1994) 0.95
Physiological effects of HIV infection on human intestinal epithelial cells: an in vitro model for HIV enteropathy. AIDS (1994) 0.94
Inactivation of human immunodeficiency virus by Betadine products and chlorhexidine. J Acquir Immune Defic Syndr (1989) 0.94
Antiretroviral therapy: reverse transcriptase inhibition. Antimicrob Agents Chemother (1992) 0.92
Both serum HIV type 1 RNA levels and CD4+ lymphocyte counts predict clinical outcome in HIV type 1-infected subjects with 200 to 500 CD4+ cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. AIDS Res Hum Retroviruses (2000) 0.92
Effects of recombinant soluble CD4 (rCD4) on HIV-1 infection of monocyte/macrophages. J Infect Dis (1990) 0.90
Frequent identification of HIV-1 DNA in bronchoalveolar lavage cells obtained from individuals with the acquired immunodeficiency syndrome. Am Rev Respir Dis (1991) 0.90
Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. Transplantation (1995) 0.90
Serologic diagnosis of focal pneumonia caused by Cryptococcus neoformans. Am Rev Respir Dis (1985) 0.88
Activation and suppression of herpes simplex virus in a human T lymphoid cell line. J Immunol (1981) 0.88
Antiretroviral resistance testing comes of age. Antivir Ther (2000) 0.88
Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy. J Infect Dis (2001) 0.87
Antiretroviral treatment for HIV infection in developing countries: an attainable new paradigm. Nat Med (2003) 0.86
Parasitic sinusitis and otitis in patients infected with human immunodeficiency virus: report of five cases and review. Clin Infect Dis (1997) 0.86
Disseminated cryptococcosis diagnosed on peripheral blood smear in a patient with acquired immunodeficiency syndrome. Am J Med (1990) 0.85
Viral aseptic meningitis in the United States: clinical features, viral etiologies, and differential diagnosis. Curr Clin Top Infect Dis (1992) 0.85
Alpha interferon and acyclovir treatment of herpes simplex virus in lymphoid cell cultures. Antimicrob Agents Chemother (1982) 0.84
Neuromuscular function in HIV infection: analysis of a placebo-controlled combination antiretroviral trial. AIDS Clinical Group 175/801 Study Team. AIDS (1998) 0.84
Transient and stable ionic permeabilization of isolated skeletal muscle cells after electrical shock. J Burn Care Rehabil (1993) 0.82
HTLV-III/LAV infection in kidney and liver transplantation. Transplant Proc (1987) 0.82
Effect of the calcium channel blocker verapamil on human immunodeficiency virus type 1 replication in lymphoid cells. J Infect Dis (1991) 0.81
Diarrheal disease in patients infected with human immunodeficiency virus in Bangkok, Thailand. Am J Trop Med Hyg (1999) 0.80
Pulmonary complications of orthotopic liver transplantation. Transplantation (1986) 0.80
The pathophysiology of enhanced susceptibility to murine cytomegalovirus respiratory infection during short-term exposure to 5 ppm nitrogen dioxide. Am Rev Respir Dis (1988) 0.79
Pathogenicity and diversity of HIV and implications for clinical management: a review. J Acquir Immune Defic Syndr (1994) 0.78
Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: combination therapy. Hosp Pract (Off Ed) (1992) 0.77
Ganciclovir hepatotoxicity. Pharmacotherapy (1987) 0.77
Virologic and regimen termination surrogate end points in AIDS clinical trials. JAMA (2001) 0.77
Evaluation of an infectivity standard for real-time quality control of human immunodeficiency virus type 1 quantitative micrococulture assays. Participating Laboratories of The AIDS Clinical Trials Group. J Clin Microbiol (1996) 0.77
Herpes simplex virus replication in interleukin-2-stimulated human T cells. J Infect Dis (1985) 0.77
Effects of recombinant interleukin-2 on resting human T lymphocytes. J Biol Response Mod (1986) 0.77
Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individuals. Antivir Ther (1997) 0.76
Human T-lymphotropic virus type III infection in previously immunocompromised hosts. J Clin Oncol (1986) 0.75
Treatment of HIV infection: the antiretroviral nucleoside analogues. Introduction. Hosp Pract (Off Ed) (1992) 0.75
In vivo effects of interleukin 3 in HIV type 1-infected patients with cytopenia. AIDS Res Hum Retroviruses (1995) 0.75
Infusion phlebitis associated with a programmable syringe-pump system versus gravity-feed minibottles. Clin Pharm (1987) 0.75
Isolation of human immunodeficiency virus and serum neutralising antibody. Lancet (1986) 0.75
Infectious complications with the use of cyclosporine versus azathioprine after cadaveric kidney transplantation. Am J Surg (1987) 0.75
Lack of in vivo effect of granulocyte-macrophage colony-stimulating factor on human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (1996) 0.75
Acyclovir-associated fever: a case report. Pharmacotherapy (1987) 0.75
Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine. AIDS Res Hum Retroviruses (2000) 0.75
An approach to antiretroviral treatment of HIV disease. Nucleoside monotherapy. Hosp Pract (1995) (1995) 0.75